Novacyt Sa Stock Performance
| NVYTF Stock | USD 0.64 0.06 8.57% |
The company secures a Beta (Market Risk) of -0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Novacyt SA are expected to decrease at a much lower rate. During the bear market, Novacyt SA is likely to outperform the market. At this point, Novacyt SA has a negative expected return of -0.52%. Please make sure to verify Novacyt SA's value at risk and day median price , to decide if Novacyt SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novacyt SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 91.8 M | |
| Total Cashflows From Investing Activities | -5 M |
Novacyt |
Novacyt SA Relative Risk vs. Return Landscape
If you would invest 96.00 in Novacyt SA on September 19, 2024 and sell it today you would lose (32.00) from holding Novacyt SA or give up 33.33% of portfolio value over 90 days. Novacyt SA is currently producing negative expected returns and takes up 4.6266% volatility of returns over 90 trading days. Put another way, 41% of traded pink sheets are less volatile than Novacyt, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novacyt SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novacyt SA's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novacyt SA, and traders can use it to determine the average amount a Novacyt SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1131
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVYTF |
Estimated Market Risk
| 4.63 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.52 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novacyt SA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novacyt SA by adding Novacyt SA to a well-diversified portfolio.
Novacyt SA Fundamentals Growth
Novacyt Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novacyt SA, and Novacyt SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novacyt Pink Sheet performance.
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (50.49 M) | |||
| Shares Outstanding | 70.63 M | |||
| Price To Earning | 0.51 X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 95.78 M | |||
| EBITDA | (1.71 M) | |||
| Cash And Equivalents | 99.65 M | |||
| Cash Per Share | 1.41 X | |||
| Total Debt | 1.67 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 1.88 X | |||
| Cash Flow From Operations | 15.69 M | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 183.7 M | |||
About Novacyt SA Performance
By analyzing Novacyt SA's fundamental ratios, stakeholders can gain valuable insights into Novacyt SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Novacyt SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novacyt SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people.Things to note about Novacyt SA performance evaluation
Checking the ongoing alerts about Novacyt SA for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novacyt SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novacyt SA generated a negative expected return over the last 90 days | |
| Novacyt SA has some characteristics of a very speculative penny stock | |
| Novacyt SA has high historical volatility and very poor performance | |
| The company reported the revenue of 95.78 M. Net Loss for the year was (9.73 M) with profit before overhead, payroll, taxes, and interest of 64.87 M. |
- Analyzing Novacyt SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novacyt SA's stock is overvalued or undervalued compared to its peers.
- Examining Novacyt SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novacyt SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novacyt SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novacyt SA's pink sheet. These opinions can provide insight into Novacyt SA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Novacyt Pink Sheet analysis
When running Novacyt SA's price analysis, check to measure Novacyt SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt SA is operating at the current time. Most of Novacyt SA's value examination focuses on studying past and present price action to predict the probability of Novacyt SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt SA's price. Additionally, you may evaluate how the addition of Novacyt SA to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |